Yes, the value of each script to the company is vastly different...

Yes, the value of each script to the company is vastly different (higher) to that incurred by the insured patient. When looking in combination at the addressable market, the safety profile, the monopolistic position, and the regulatory approval in the most important global market etc, the revenue targets are not lofty as it relates to current and future valuation. At $600 a pop to BOT, we are talking 50k scripts, not 800,000.

separately and just as a point of interest, BOT is considered a positive social impact stock. It’s featuring more and more in impact investment portfolios, increasingly screened in. I think this will continue, especially if future success with the anti microbial and acne treatments is achieved.